ErVimmune Secures €17m to Push Cancer Vaccine Towards First-in-Human Trial
ErVimmune, a preclinical biotechnology company developing cell therapies and cancer vaccines, has announced a total of €17 million in new funding – a substantial boost that the company says will accelerate progress on its lead cancer vaccine candidate, ErVac01.
At the centre of the announcement is ErVac01’s scientific premise: a heterologous vaccine formulation built from a collection of human endogenous retrovirus (HERV)-derived epitopes. In simple terms, the vaccine is designed around carefully selected immune targets that are intended to be recognised by a broad range of people.
The company says the formulation has been constructed to cover the majority of the worldwide population in terms of HLA alleles – a key consideration, as HLA diversity influences how effectively different individuals present antigens to their immune system.
Crucially, ErVimmune’s approach aims to sidestep one of the biggest practical barriers in cancer vaccine development: the need to manufacture a bespoke therapy for every patient. By focusing on antigens shared across multiple patients and tumours, the company believes ErVac01 could be produced as a ready-to-use, off-the-shelf product, rather than a fully personalised vaccine created patient by patient.
If the concept holds up in the clinic, it could simplify production timelines and logistics – two factors that often make advanced therapies difficult to scale.
The company is positioning ErVac01 for a particularly challenging target: tumours that are unresponsive to current immunotherapies, commonly referred to as “cold” tumours. These cancers have a reputation for evading immune detection or failing to generate the type of immune activity that many immunotherapies rely upon.
ErVimmune’s stated ambition is to bring immune engagement to tumour types where today’s tools frequently underperform, including diseases such as triple-negative breast cancer and ovarian cancer.
The new funding is expected to support a pivotal transition from preclinical work to early clinical development. ErVimmune says the financing will allow it to advance into a first-in-human clinical trial of ErVac01, with the initial focus on assessing safety and immunogenicity – in other words, whether the vaccine is safe and whether it successfully triggers the intended immune response in people.
Beyond the clinical programme itself, the company noted an additional advantage: the round is expected to help ErVimmune access non-dilutive funding from Bpifrance and the France 2030 programme.
For early-stage biotech, this matters – non-dilutive capital can extend a runway without immediately increasing ownership dilution, offering flexibility as clinical plans become more ambitious and costly.
The round drew participation from investors including Seventure Partners and SPRIM Global Investments. In commentary accompanying the announcement, the CEO and managing partner at Seventure Partners described the move to bring ErVac01 into the clinic as a “decisive step” towards translating the vaccine platform into tangible benefits for patients – framing the next phase as the point where promise begins to meet proof.
From ErVimmune’s side, a founder and board member characterised the funding as a “critical milestone” in bringing an off-the-shelf cancer vaccine to the clinic, adding that the approach has the potential to transform treatment options for patients facing difficult-to-treat cancers.
It is the kind of claim biotech companies often make at this stage – but one that will now be tested against the reality of human data, where safety, immune activation, and early biological signals must align to justify larger trials.
ErVimmune also highlighted that this latest round builds on a foundation of sustained institutional and ecosystem backing. The company has received financial support from Bpifrance, Cancéropôle Lyon Auvergne-Rhône-Alpes, and the Agence Nationale de la Recherche (ANR) since its founding.
It has also been supported by medical and technology organisations, including the Paris Saclay Cancer Cluster (PSCC) in 2024 and the NETVA programme in 2025 – a track record that suggests growing confidence in both the platform and the team executing it.
In many ways, the announcement is a snapshot of modern cancer innovation: scientific ambition paired with the push for scalable manufacturing, and a clear focus on areas where current treatments still fall short.
With €17m now secured, ErVimmune’s next steps are equally clear – move ErVac01 into a first-in-human trial, demonstrate safety and immunogenicity, and use that evidence to chart a credible path towards tackling “cold” tumours that continue to resist today’s immunotherapy playbook.
In conclusion
ErVimmune’s funding round marks a significant preclinical-to-clinical inflection point.
Backed by new investors and supported by French innovation programmes and research networks, the company is betting that a broad-coverage, HERV-epitope, off-the-shelf vaccine strategy can open fresh options for patients with hard-to-treat cancers – starting with the first human trial that will determine whether the platform can deliver on its early promise.
News Credits: ErVimmune raises 17m euros in funding to develop cancer vaccine
Things you may also like:
- Ipsen Brings Fresh Stroke Spasticity Insights to TOXINS 2026
- Gosh! Serves Up Falafel “Food to Go” as Fibre Fever Takes Hold
- FDA Grants Priority Review to argenx’s VYVGART